about

our purpose:
precision medicine

TAmiRNA is a biotech company specialized in the discovery and validation of microRNA biomarkers. Our mission is to provide validated diagnostic solutions to patients with serious aging-related illnesses. We aim to improve and prolong patient stability, health and quality of life with increasing age.

our technology:
microRNA signatures

We are specialized in biomarker development using blood-circulating microRNAs – evolutionary conserved regulators of gene expression and cell/tissue function. We develop diagnostic algorithms (“signatures”) based on the logic combination of microRNA levels and clinical parameters.

age_associated_diseases

our focus:
age-associated diseases

TAmiRNA is actively involved in R&D projects in osteoporosis (OP), cardiovascular disease (CVD), liver disease and aging. OP and CVD are multifactorial illnesses. Using microRNA signatures we aim to decode the contributing disease factors on a personalized level, and to use this knowledge for better diagnosis.

TAmiRNA_team_2019

our team

CEO and co-founder

Matthias Hackl graduated in the area of Biotechnology from the University of Natural Resources and Life Sciences Vienna (Boku) in 2012. His studies of microRNA function in mammalian cell lines and model systems of Ageing involved rotations through labs at the University of Georgia and Minnesota in the United States as well as University Bielefeld in Germany. Matthias has won two private company grants for developing applications of PCR and Flow Cytometry based microRNA quantification tools and was honored by the Austrian Association of Molecular Life Sciences and Biotechnology for his achievements during his PhD. He has authored 30 publications and two book chapters in the field of microRNA biology and held a one-year PostDoc position in microRNA-based cell engineering at the Vienna Institute of Biotechnology before joining TAmiRNA. Matthias Hackl is also co-founder of Remute Bio GmbH, founded in 2016.

CFO and co-founder

Otto Kanzler has more than 30 years experience in process- and business development in the biotech industry. Since 2007 he is serving as Management Consultant for production and technology-development for biotech- and pharma- industry, specified for strategic and economic issues. He is a serial entrepreneur having founded and co-founded several companies, all of which are still active – CEO / CFO of Remute Bio GmbH (founded 2016), co-founder and interim CEO / CFO of Phoenestra GmbH (founded 2015), Advisor of DirectSens GmbH (since 2015), co-founder and CFO of Syconium Lactic Acid GmbH (founded 2014),  co-founder and CFO of TAmiRNA GmbH (founded 2012),  co-founder and CEO of Evercyte GmbH und Chorus GmbH, (both founded 2011). Between 1993 and 2007 he was department head at Boehringer Ingelheim Austria, responsible for the economic issues of the industrial biopharmaceutical business. Prior to this he was head of process development for biopharmaceutical processes at Boehringer Ingelheim Austria (1981-1993).

Senior Project Manager

Hanna Dellago holds a master’s degree in genetics and microbiology from the University of Vienna and a PhD degree in Biotechnology from the University of Natural Resources and Life Sciences Vienna (BOKU). Her PhD and PostDoc studies in the lab of Prof. Johannes Grillari focused on the functional characterization of proteins and microRNAs in cellular and organismal aging, and involved stages at the University of Toronto, Canada, and the University of Dundee, Scotland. Hanna Dellago joined TAmiRNA in 2016 as scientific writer. Since 2018, she is senior project manager at TAmiRNA in charge of B2B and customer communication, conceptualization and processing of contract research projects.

Scientific advisor and co-founder

Johannes Grillari has more than 10 years of experience as a group leader in cellular and molecular aging research. Since 2006 he is associate professor at the Department of Biotechnology, University of Natural Resources and Life Sciences Vienna, Austria. He did his PhD degree between 1996 and 1999 on senescence of endothelial cells and worked as a visiting scientist at the University of Dundee, Scotland, UK. He has authored and co-authored more than 63 scientific articles and book chapters, 6 patents, and was invited as speaker more than 70 times to international meetings. Furthermore, Johannes Grillari is co-founder and CSO of Evercyte GmbH (est. 2011), co-founder of Phoenestra GmbH (founded 2015) and co-founder and scientific advisor of Remute Bio GmbH (2016).

Scientific advisor and co-founder

Regina Grillari is associate professor for cellular biology since 2008 and has been leading a group focused on cellular immortalization and cell line development for more than 10 years at the Department of Biotechnology, University of Natural Resources and Applied Life Sciences Vienna, Austria. She achieved her PhD in 2000 on immortalization of human cells and recombinant protein expression and was appointed to receive the Prof. Anton Kurir habilitation award in 2009.  In 2012 she received the “Phoenix Award” for successful academic entrepreneurship from the Austrian Ministry of Science and Research and 2015 she achieved third place of the Houska Award of the B&C Holding. Furthermore Regina Grillari has authored and co-authored more than 50 scientific publications and book chapters, 4 patents. In addition she is co-founder and CTO of Evercyte GmbH (est. 2011), co-founder of Phoenestra GmbH (2015) and also co-founder and scientific advisor of Remute Bio GmbH (2016).

advisory board

Scientific advisor and co-founder

Regina Grillari is associate professor for cellular biology since 2008 and has been leading a group focused on cellular immortalization and cell line development for more than 10 years at the Department of Biotechnology, University of Natural Resources and Applied Life Sciences Vienna, Austria. She achieved her PhD in 2000 on immortalization of human cells and recombinant protein expression and was appointed to receive the Prof. Anton Kurir habilitation award in 2009.  In 2012 she received the “Phoenix Award” for successful academic entrepreneurship from the Austrian Ministry of Science and Research and 2015 she achieved third place of the Houska Award of the B&C Holding. Furthermore Regina Grillari has authored and co-authored more than 50 scientific publications and book chapters, 4 patents. In addition she is co-founder and CTO of Evercyte GmbH (est. 2011), co-founder of Phoenestra GmbH (2015) and also co-founder and scientific advisor of Remute Bio GmbH (2016).

Scientific advisor and co-founder

Johannes Grillari has more than 10 years of experience as a group leader in cellular and molecular aging research. Since 2006 he is associate professor at the Department of Biotechnology, University of Natural Resources and Life Sciences Vienna, Austria. He did his PhD degree between 1996 and 1999 on senescence of endothelial cells and worked as a visiting scientist at the University of Dundee, Scotland, UK. He has authored and co-authored more than 63 scientific articles and book chapters, 6 patents, and was invited as speaker more than 70 times to international meetings. Furthermore, Johannes Grillari is co-founder and CSO of Evercyte GmbH (est. 2011), co-founder of Phoenestra GmbH (founded 2015) and co-founder and scientific advisor of Remute Bio GmbH (2016).

Scientific advisor

Since 1998 Heinz Redl is the director of the Ludwig Boltzmann Institute for Experimental and Clinical Traumatology. In his group, Dr. Redl has pioneered research in the field of tissue/bone regeneration and has lead the development of innovative approaches to bone healing.

Prof. Redl assists in TAmiRNA in the design and conduction of pre-clinical trials.

Scientific advisor

Peter Pietschmann is Deputy Head at the Department of Pathophysiology at the Medical University of Vienna since 2006 after being appointed as Associate Professor in 2002. His group is conducting research on the pathophysiology of bone fragility and the relation of bone strength to gene expression. He has published 169 papers in peer-reviewed journals in the area of Osteoporosis and was honored with several awards. Dr. Pietschmann is currently serving as President of the Austrian Society of Bone and Mineral Research, and former president of the Austrian Society of Geriatrics & Gerontology.

Peter Pietschmann supports TAmiRNA in scientific and strategic decisions in developing novel biomarkers for risk assessment in osteoporosis.

Scientific advisor

As a former professor of the Medical University of Vienna, Prof. Woloszczuk was involved in the development of numerous biochemical biomarkers and diagnostic tests for bone diseases. He co-founded the Biomedica GmbH, which specializes in the development and commercialization of diagnostic products. 

Prof. Woloszczuk supports TAmiRNA in strategic decisions in respect to development and marketing of its novel biomarker tests.

our partners

advanceCOR

advanceCOR
Partner in the Eurostars project entitled: ”thrombomiR – a novel microRNA-based platelet function biomarker for personalized anti-thrombotic treatment”.
www.advancecor.de

THP

THP Medical Products
Distribution Partner for Austria, Switzerland and Southern Germany
www.thp.at/

FFG

Die Österreichische Forschungsförderungsgesellschaft FFG
“Basisprogramm” financing of R&D cooperations of TAmiRNA.
www.ffg.at

BioVendor

Biovendor
Distribution Partner for Slovakia, Czech Republic, Scandinavia, Western Europe and North America
www.biovendor.com

Biomedica

Biomedica
Central European Distribution partner
www.bmgrp.com/home/

Vivomicx

Vivomicx
Partner in preclinical drug discovery and  drug development
www.vivomicx.eu

SimplicityBio

SimplicityBio
Partner in biomarker development services.
www.simplicitybio.com

TELLVienna
BOKU

BOKU – VIBT
Partner for assay development and functional in vitro screenings of microRNAs that are associated with age-related disorders.
www.boku.ac.at/vibt.html

Evercyte

Evercyte GmbH
Partner in the application of pre-clinical models for toxicity and efficacy testing of novel drug candidates
www.evercyte.com

GrillariLabs

Grillari Labs
Partner in development of basic research models to gain a better understanding microRNA function in age-related disorders such as Osteoporosis, Cardiovascular Disease or Neurodegenerative Disease
www.grillarilabs.at

Cardiolinc

Cardiolinc
Partner for collaborating on projects and translational research.
www.cardiolinc.org

LBI

Ludwig Boltzmann Institute for Experimental and Clinical Traumatology

www.trauma.lbg.ac.at/de

Austrian Cluster for Tissue Regeneration

Austrian Cluster for Tissue Regeneration

www.tissue-regeneration.at

Innofly

Innofly Management
Supports TAmiRNA in backoffice activities
www.innofly.at

TransformScience

Transform Science
Partner for the implementation of quality driven processes.
www.transform-science.com

job offers

passion and motivation

At TAmiRNA we are looking for people passionate about science and who are willing to contribute to a society that is healthier and more stable. We continually seek for best-qualified candidates who want to become part in our collaborative and committed team.

Interested candidates should email a cover letter and resume to office(at)tamirna.com